Nyheter

LIPIGON ENTERS LICENSING AND COLLABORATION AGREEMENT WITH COMBIGENE TO DEVELOP GENE THERAPY FOR LIPO

10 oktober, 2019

“We are very happy to enter this agreement with CombiGene ,” says Stefan K Nilsson, CEO at Lipigon. “Through the development of their epilepsy project, CombiGene has demonstrated a fantastic ability to handle the complexities of gene therapy. With our expertise in lipid biology this collaboration is a perfect match, ultimately aiming at improving the treatment for a patient group with few or no treatment options.” During the upcoming two years, the development of the lipodystrophy project will intensify. The main part of the work will be done at Lipigon and in close collaboration between the two companies.

Fler nyheter

25 augusti, 2020, Övrig nyhet

Lipigon-CombiGene collaboration reaches milestone

2 mars, 2016, Övrig nyhet

MIKAEL ELOFSSON INTERVIEWED AT ADD 2016

1 mars, 2016, Övrig nyhet

AVAILABLE POSITIONS

3 februari, 2016, Övrig nyhet

LIPIGON AWARDED CONNECT´S PITCH PRIZE

9 december, 2015, Övrig nyhet

LIPIGON PATENT APPLICATION PUBLISHED

1 september, 2015, Övrig nyhet

LIPIGON SCIENTISTS PUBLISH IN PRESTIGIOUS JOURNAL

27 juni, 2014, Övrig nyhet

LIPIGON SCIENTISTS IDENTIFIES LPL ACTIVATORS

26 januari, 2014, Övrig nyhet

LIPIGON ATTENDS: BIOTECH UMEÅ INVESTMENT DAY

17 januari, 2014, Övrig nyhet

LIPIGON ATTENDS: SWISS-SWEDEN

Nyheter

2 juli, 2021, Pressmeddelande

Lipigons vd intervjuas av Finwire

I en Sitdown-intervju med Finwire berättar Lipigons vd Stefan K. Nilsson om huvudprojektet Lipisense...

2 juli, 2021, Pressmeddelande

Lipigon kontrakterar CRO för den kommande fas I-studien med Lipisense

Lipigon Pharmaceuticals AB ("Lipigon") som utvecklar läkemedel mot sjukdomar orsakade av rubbningar ...

1 juli, 2021, Pressmeddelande

Analysguiden: Låg värdering och välfylld kassa

Analysguiden inleder bevakning av Lipigon med en riktkurs på 17 kronor per aktie, baserat på Lipisen...